For HR-positive, HER2-negative breast cancer patients, the abemaciclib (BESIDX) from Lao Big Bear Pharmaceutical not only continues the clinical value of CDK4/6 inhibitors as a key targeted therapy, but also, as a generic drug, lowers the financial threshold, allowing more patients to gain access to sustained treatment.
How much does Lao Big Bear generic abemaciclib cost?
Lao Big Bear generic abemaciclib is available in a规格 of 150mg*56 tablets per box, with a price of approximately $227. The exact price may be affected by various factors, and the actual selling price shall prevail.
Mechanism of action of abemaciclib
Abemaciclib (generic name: abemaciclib) is an oral small-molecule cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor developed by Eli Lilly. It was first approved by the FDA in 2017, and its indications have been continuously expanded. It has now become an important tool in the full-course management of HR-positive/HER2-negative breast cancer.
Precise mechanism of action: After CDK4/6 binds to cyclin D, it phosphorylates the retinoblastoma protein (Rb), thereby driving cells from G1 phase into S phase, promoting DNA replication and cell division. Abemaciclib, through potent and selective inhibition of CDK4/6, blocks Rb phosphorylation, arrests tumor cells in G1 phase, and induces senescence and apoptosis. In vitro and xenograft models have shown that continuous uninterrupted dosing significantly reduces tumor volume, and combination with anti-estrogen agents (such as aromatase inhibitors or fulvestrant) has synergistic effects.
Approved indications cover all lines of therapy: ① In combination with an aromatase inhibitor for initial endocrine therapy of postmenopausal HR+/HER2- advanced or metastatic breast cancer (based on MONARCH3); ② In combination with fulvestrant for HR+/HER2- advanced or metastatic breast cancer with disease progression after endocrine therapy (based on MONARCH2); ③ As monotherapy for HR+/HER2- advanced breast cancer patients who have progressed after endocrine therapy and chemotherapy in the metastatic setting (based on MONARCH1). This makes abemaciclib the only CDK4/6 inhibitor that can be used both as monotherapy and in combination with endocrine therapy.
Storage: Store at 20–25°C room temperature, avoid moisture and keep out of reach of children.
The multi‑indication coverage of this drug provides flexible options for patients at different treatment stages, especially for those with endocrine resistance or who cannot tolerate chemotherapy, offering an effective and relatively low‑toxicity alternative.
Recommended dosage of abemaciclib
Correctly mastering the dosage regimen, administration methods, and potential drug interactions of abemaciclib is the foundation for ensuring efficacy and safety. At the same time, attention should be paid to individualized adjustments for special populations (such as those with hepatic/renal impairment, and women of childbearing potential).
Standard recommended dose: When used in combination with an aromatase inhibitor or fulvestrant, the recommended starting dose is 150 mg twice daily (morning and evening, approximately 12 hours apart); for monotherapy, it is 200 mg twice daily. Each dose may be taken with or without food; tablets should be swallowed whole, not chewed, crushed, or split; if the tablet is broken, cracked, or shows fissures, it should be discarded. Try to take the medication at the same time each day. If vomiting or a missed dose occurs, do not make up the dose; take the next dose as scheduled, and never double the dose.
Dose adjustment principles: Based on individual safety and tolerability, the physician may interrupt dosing, reduce the dose (first to 100 mg twice daily, and if necessary, further to 50 mg twice daily), or permanently discontinue. After dose reduction, do not resume the original dose without medical advice.
Important drug interactions: Abemaciclib is primarily metabolized by the CYP3A enzyme system. Concomitant use with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) should be avoided; if co‑administration with a strong inhibitor is unavoidable, reduce the dose to 100 mg twice daily. Also avoid strong CYP3A inducers (e.g., rifampin, phenytoin) as they may reduce efficacy. In addition, grapefruit and grapefruit juice should be avoided during treatment, as they can increase blood concentrations and raise the risk of toxicity.
Special population warnings: Women of childbearing potential must have a negative pregnancy test before starting treatment; highly effective contraceptive measures must be used during treatment and for at least 3 weeks after the last dose. Abemaciclib may affect male fertility; men with reproductive plans should consult a reproductive medicine specialist in advance. Breastfeeding women are advised not to breastfeed during treatment and for at least 3 weeks after the last dose. Patients with severe hepatic impairment or end‑stage renal disease should use with caution, and may require adjusted starting doses or enhanced monitoring.
All patients should carry a medication list and proactively inform their healthcare provider of all prescription drugs, over‑the‑counter medications, vitamins, and herbal supplements they are using, to guard against potential interaction risks.
